Novartis wins FDA nod for Rydapt, a new targeted drug for acute myeloid leukemia epalmer Fri, 04/28/2017 – 11:41 More: Novartis wins FDA nod for Rydapt, a new targeted drug for acute myeloid leukemia Source: fierce
read moreAstraZeneca investors rebel—again—at CEO Pascal Soriot’s 68% bonus-pay boost tracy Fri, 04/28/2017 – 10:38 More: AstraZeneca investors rebel—again—at CEO Pascal Soriot's 68% bonus-pay boost Source: fierce
read moreMerck’s Vytorin set for massive sales slide as generics hit esagonowsky Fri, 04/28/2017 – 10:37 More: Merck's Vytorin set for massive sales slide as generics hit Source: fierce
read moreSanofi enjoys solid Q1, despite continuing erosion of Lantus sales in U.S. epalmer Fri, 04/28/2017 – 10:22 More: Sanofi enjoys solid Q1, despite continuing erosion of Lantus sales in U.S. Source: fierce
read moreThe National Institute for Health and Care Excellence is backing the use of Janssen’s biologic Stelara to treat adult patients with moderately to severely active Crohn’s disease. More: NICE backs new option for Crohn’s disease Source: News
read moreIt is now looking likely that some patients with relapsed/refractory (R/R) Hodgkin lymphoma will be able to get routine access to Takeda’s Adcetris on the NHS after a major u-turn by cost regulators. More: NICE u-turn recommends some access to
read more© 1994 - 2026 B.M. Pharmaceuticals